Quest for life-long protection by vaccination.

Dowdle, Walter R.; Orenstein, Walter A.

doi:10.1073/pnas.91.7.2464

Cited by 9 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The result of this study showed that top 3 attributes with the highest weight from respondents were reported to be premature deaths averted per year (19.49%); incident cases prevented per year (15.55%); and cost-effectiveness (13.10%). The result on this study strengthened the result from previous studies, which confirmed that the great potential of vaccinations on reducing VPDs and the cost-effectiveness of vaccinations were major factors on the investment of vaccination [31][32][33]. A study by Quilici et al in 2015, reported that vaccination programs represent a long-term investment in future generations since vaccinations have contributions to improve population health and economic growth [31].…”

Section: Discussionsupporting

confidence: 84%

“…Specifically, mortality rate and incident case due to VPDs were strongly associated with a country's economic, social conditions and the performance of its healthcare system [31]. In addition, vaccination has been highlighted to be one of the most cost-effective health interventions to save people's lives, improve health and ensure long-term prosperity due to the lifelong protection that vaccines can provide in most cases [32]. Vaccination also could impact the long-term development in a country through economic benefits, such as cognitive development, educational attainment, labor productivity, income, savings, and investment [33].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART vaccines)

Suwantika

Purwadi

Zakiyah

et al. 2021

Expert Review of Vaccines

View full text Add to dashboard Cite

Background: Decision-making processes regarding new vaccine prioritizations are complex. The objective of this study was to prioritize the introduction of new vaccines in Indonesia. Methods: A multi-criteria decision analysis (MCDA) was applied in this study. A preliminary data collection form was developed to collect country-specific data in relation to 30 pre-defined attributes. In particular, an open-ended questionnaire was conducted among targeted respondents from global level, national level and vaccine manufacturers, which were involved in the financial flows of new vaccine procurement in Indonesia. For setting new vaccines priorities, targeted respondents were asked to assign weight on 10 selected criteria. Results: Top 3 attributes with the highest weight from respondents were premature deaths averted per year, incident cases prevented per year, and cost-effectiveness. Applying criteria scores and weight assessment, the result showed that PCV, rotavirus, HPV, and JE would be on the 1st, 2nd, 3rd, and 4th rank for setting new vaccine priority in Indonesia. There was a significant difference score (p value <0.05) between all these vaccines. Conclusions: PCV, rotavirus and HPV vaccines should be more prioritized than JE vaccine. This ranking is in line with the WHO's priority list, which potentially illustrates the validity and usefulness of our MCDA-approach.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART vaccines)

Suwantika

Purwadi

Zakiyah

et al. 2021

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Mass vaccination is an important measure for the control of infectious diseases [1]. Vaccination protects directly on an individual level and indirectly on a community level.…”

Section: Introductionmentioning

confidence: 99%

Model‐based estimation of vaccine effects from community vaccine trials

Longini

Halloran

Nizam

2002

Statistics in Medicine

View full text Add to dashboard Cite

Community vaccine trials are becoming increasingly important to assess both the direct and indirect community level effects of vaccination. In this paper, we present statistical methods to analyse such trials, using a design with several matched pairs of communities. The communities are matched on similarities in infection transmission as reflected through the basic reproduction number. Two methods of analysis are presented and compared. The first is simple empirical estimation of vaccine effects. Summary measures of these effects are constructed by reciprocal variance weighted averages across the community pairs. The second is likelihood-based where we derive a mixed effects epidemic model. This model takes the intercommunity variability into account through a random effect on the basic reproduction number. With this model, we derive a distribution-free estimator for the variance of the random effect. We use simulated epidemics to explore the performance of the two estimation methods for different numbers of community pairs and different levels of inter-pair variability. Both methods provide acceptable estimates in terms of bias and precision under reasonable conditions. Although the empirical approach involves fewer assumptions than the model-based approach, the resulting vaccine effectiveness estimates are only applicable to the vaccination fraction tested in the trial. In contrast, the model-based approach can be used to predict the vaccine effectiveness at vaccination fractions other than those used in the trial. Thus, it can be used as a public health policy tool for predicting the community level effects of vaccination. We demonstrate such use by predicting total vaccine effectiveness for the whole range of vaccination fractions.

show abstract

“…1 In the Netherlands, MMR vaccination was implemented in 1987 by offering vaccinations to children at the age of 14 months and 9 y As a consequence, the annual mumps incidence decreased dramatically as in other countries where mumps vaccination was implemented. 2,3 Although it was assumed that mumps vaccination induces life-long protection, 4 several mumps outbreaks, especially among vaccinated student populations, have been reported during the last decade in various countries where mumps vaccination has been implemented into their national immunization programs. [5][6][7][8][9][10][11][12][13][14] In 2009-2012, a mumps epidemic (genotype G) arose that spread across multiple locations within the Netherlands, in which also primarily vaccinated students were affected.…”

Section: Introductionmentioning

confidence: 99%

Dynamics of the serologic response in vaccinated and unvaccinated mumps cases during an epidemic

Kaaijk

Gouma

Hulscher

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Abbreviations: MMR, measles mumps and rubella; ND 50 , reciprocal virus-neutralizing antibody dose; VN, virus-neutralizing antibody; RU/ml, RIVM units per ml; GMC, geometric mean concentration; 95% CI, lower and upper 95% confidence intervals of GMCIn the last decade, several mumps outbreaks were reported in various countries despite high vaccination coverage. In most cases, young adults were affected who have acquired immunity against mumps solely by vaccination and not by previous wild-type mumps virus infection. To investigate mumps-specific antibody levels, functionality and dynamics during a mumps epidemic, blood samples were obtained longitudinally from 23 clinical mumps cases, with or without a prior history of vaccination, and from 20 healthy persons with no serological evidence of recent mumps virus infection. Blood samples from mumps cases were taken 1-2 months and 7-10 months after onset of disease. Both vaccinated and unvaccinated mumps cases had significantly higher geomean concentrations of mumps-specific IgG (resp. 13,617 RU/ml (95% CI of 9,574-19,367 RU/ml) vs. 1,552 (445-5412) RU/ml at 1-2 months; and 6,514 (5,247-8,088) RU/ml vs. 1,143 (480-2,725) RU/ml at 7-10 months) than healthy controls (169 (135-210) RU/ml) (p D 0.001). Patterns in virus-neutralizing (VN) antibody responses against the mumps vaccine virus were similar, vaccinated and unvaccinated mumps cases had significantly higher ND 50 values at both time points of sampling (resp 4,695 (3,779-5,832) RU/ml vs. 1,533 (832-2,825) RU/ml at 1-2 months; 2,478 (1,968-3,122) RU/ml vs. 1,221 (1,029-1,449) RU/ml at 7-10 months) compared with (previously vaccinated) healthy controls (122 (196-76)) RU/ml) (p D 0.001) The unvaccinated mumps cases had significantly lower mumps-specific IgG and VN antibody concentrations at both sampling points compared with previously vaccinated cases, but their antibody concentrations did not differ significantly at the 2 time points. In contrast, the mumps-specific IgG and VN antibody concentrations of the previously vaccinated mumps cases were significantly higher within the first 2 months after onset of mumps and declined thereafter, characteristic for a secondary response. A moderate correlation was found between the level of mumps-specific IgG serum antibodies and VN antibodies for the mumps cases (r D 0.64; p<0.001).

show abstract

Quest for life-long protection by vaccination.

Abstract: Life-long protection from disease through immunization can be accomplished through individual or com-

Cited by 9 publications

References 18 publications

Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART vaccines)

Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART vaccines)

Model‐based estimation of vaccine effects from community vaccine trials

Dynamics of the serologic response in vaccinated and unvaccinated mumps cases during an epidemic

Contact Info

Product

Resources

About